Exelixis | EXEL - Lieferungen Und Leistungen





Lieferungen Und Leistungen Veränderung Datum
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
Agios Pharmaceuticals USD 18.36M 1.2M 2025-12
Akebia Therapeutics USD 21.18M 11.1M 2025-12
Amgen USD 20.89B 1.25B 2025-12
AstraZeneca USD 25.28B 252M 2025-12
Bayer EUR 7.08B 700M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Bristol-Myers Squibb USD 4.29B 1.14B 2025-09
Cytokinetics USD 105.62M 83.53M 2025-12
Eisai JPY 85.49B 4.76B 2025-12
Eli Lilly USD 5.38B 1.12B 2025-12
Esperion Therapeutics USD 65.07M 12.44M 2025-12
Exelixis USD 29.62M 4.27M 2025-12
Genmab DKK 6M 2M 2025-09
Glaxosmithkline GBP 20.72B 346.14M 2025-12
Incyte USD 1.63B 1.46B 2025-12
Ionis Pharmaceuticals USD 14.33M 8.47M 2025-09
MacroGenics USD 4.79M 1.15M 2025-12
Merck USD 4.15B 102M 2025-09
Moderna USD 317M 50M 2025-12
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 545.5M 425.6M 2025-12
Novartis USD 4.46B 99M 2025-12
Pfizer USD 5.02B 142M 2025-09
Puma Biotechnology USD 6.39M 962K 2025-09
Sanofi EUR 22.93B 2.89B 2025-12
Takeda JPY 467.59B 28.61B 2025-12
Ultragenyx Pharmaceutical USD 40.57M 6.33M 2025-09
Xencor USD 10.83M 1.75M 2025-12